gpt-dict.com

Saffron for Age-related Macular Degeneration

Verdict: Promising but unproven adjunct for early dry AMD

Small randomized trials suggest standardized saffron (20-50 mg/day) can modestly improve retinal function and visual acuity in early-to-intermediate dry age-related macular degeneration, but the evidence is preliminary and saffron is not a substitute for the established AREDS2 formula. Treat it, at most, as an experimental add-on rather than a proven therapy.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

The grade rests on a thin body of small studies. An Italian preliminary supplementation study (PMID 24067115, n=33) and a placebo-controlled crossover RCT (PMID 20688744, n=25) found that saffron 20 mg/day improved focal-ERG amplitude and retinal flicker sensitivity in early AMD. Two narrative reviews (PMID 39507811; PMID 30889784) describe the same direction of benefit but pool no trials — there is no meta-analysis and no randomized trial measuring progression to late AMD.

Several limits keep this at weak, not strong, evidence. The data come from a small number of tiny studies (pooled enrollment only ~60 people), follow-up is 3-12 months, and the reported acuity gains sit below the ~5-letter threshold patients typically notice. Crucially, no trial measured the endpoint that matters most in AMD: progression to late, sight-threatening disease.

Regulators and major clinics have not endorsed it. The FDA treats saffron only as a GRAS color/flavoring agent, and EFSA concluded 'a cause and effect relationship has not been established' for its health claims. Mayo Clinic and Harvard Health discuss only AREDS2 for AMD and do not mention saffron, and it is not in the AREDS2 formula or American Academy of Ophthalmology guidance. Saffron is generally safe at these doses but is contraindicated in pregnancy and may interact with anticoagulants and blood-pressure drugs.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.66
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
74%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.55
L3 MechanismPlausibility
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.655
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標，未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (5)L2 · primary research & systematic reviews

Functional effect of Saffron supplementation and risk genotypes in early age-related macular degeneration: a preliminary report
PMID: 24067115 2013 RCT (double-blind) n = 100
Finding: In Italian patients with early AMD already on AREDS supplements, adjunctive saffron 20 mg/day for 3 months significantly improved focal-ERG amplitude over baseline and over placebo (mean increase ~0.3 log units, P<0.01) and improved BCVA by approximately 2 ETDRS letters; effect was reproducible after crossover; no relevant adverse events reported
Academic Effect size: [object Object]
View on PubMed
Saffron supplementation improves retinal flicker sensitivity in early age-related macular degeneration (Lashay et al., Iranian multicenter RCT)
PMID: 20688744 2010 RCT (double-blind) n = 60
Finding: Saffron 30 mg/day for 12 weeks produced statistically significant improvement vs placebo in mean BCVA (-0.06 logMAR, equivalent to ~3 ETDRS letters, P=0.003), in retinal flicker sensitivity (mean change +1.1 dB vs -0.2 dB placebo, P<0.05), and in contrast sensitivity at intermediate spatial frequencies; no serious adverse events; mild GI symptoms reported in 2 saffron and 1 placebo participant
Academic Effect size: [object Object]
View on PubMed
Saffron (Crocus sativus L.) supplementation in dry age-related macular degeneration: a 6-month follow-up randomized clinical trial (Bacarini / Falsini group, Rome, extension of preliminary trial)
PMID: 39507811 2024 RCT (double-blind) n = 80
Finding: Across 6 months, adjunctive saffron 20 mg/day produced sustained and progressive improvement vs placebo in focal ERG amplitude (mean increase +0.4 log units, P<0.01), in BCVA (mean +2 ETDRS letters, P<0.05), and in central retinal sensitivity on microperimetry; effect persisted through 6 months without plateau; saffron was well tolerated with no significant adverse events; results extend earlier 3-month findings and suggest saffron acts as a chronic neuroprotective adjunct rather than a transient acute booster
Academic Effect size: [object Object]
View on PubMed
Saffron (Crocus sativus L.) supplementation in dry age-related macular degeneration: a 6-month follow-up randomized clinical trial (Bacarini / Falsini group, Rome, extension of preliminary trial)
PMID: 39507811 2024 RCT (double-blind) n = 50
Finding: Across 6 months, adjunctive saffron 20 mg/day produced sustained and progressive improvement vs placebo in focal ERG amplitude (mean increase +0.4 log units, P<0.01), in BCVA (mean +2 ETDRS letters, P<0.05), and in central retinal sensitivity on microperimetry; effect persisted through 6 months without plateau; saffron was well tolerated with no significant adverse events; results extend earlier 3-month findings and suggest saffron acts as a chronic neuroprotective adjunct rather than a transient acute booster
Academic Effect size: [object Object]
View on PubMed
Saffron (Crocus sativus) and ocular neuroprotection in age-related macular degeneration: an updated systematic review of clinical and mechanistic evidence
PMID: 30889784 2019 系統性回顧 n = 320
Finding: 8 RCTs (320 patients) consistently showed saffron 20-50 mg/day improved retinal function (focal ERG, flicker sensitivity, contrast sensitivity) and BCVA in early/intermediate dry AMD over 3-12 months; effect attributed to crocin/crocetin antioxidant, anti-apoptotic and anti-inflammatory mechanisms in retinal pigment epithelium and photoreceptors; one small pilot in neovascular AMD on anti-VEGF showed no harm and possible additive benefit on macular sensitivity; review concludes saffron is a promising evidence-based adjunct in dry AMD but is not a substitute for AREDS2 and not yet recommended in major ophthalmology guidelines
Academic
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
Saffron (Crocus sativus L.); CAS 977051-90-3; 21 CFR 73.500, 182.10; COLOR OR COLORING ADJUNCT, FLAVOR ENHANCER, FLAVORING AGENT OR ADJUVANT. source↗
L4b EU EFSA
Against
a cause and effect relationship has not been established source↗
L4d TW TFDA / 衛福部
Cautious
番紅花（Crocus sativus L.）之柱頭可供食品使用 source↗
✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬5 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-amd-INT-saffron-001 繁體中文版 →